Cardio-oncology: cardiovascular complications of cancer therapy.
作者： Robert J Henning , Raymond D Harbison
关键词: Cardiology 、 Trastuzumab 、 Cardiac function curve 、 Heart failure 、 Medicine 、 Ejection fraction 、 Internal medicine 、 Myocardial infarction 、 Cardiomyopathy 、 Cardiotoxicity 、 Blood pressure
摘要: This paper focuses on three classes of commonly used anticancer drugs, which can cause cardiotoxicity: anthracyclines, monoclonal antibodies exemplified by trastuzumab and tyrosine kinase inhibitors. Anthracyclines induce cardiomyocyte necrosis fibrosis. Trastuzumab cardiac stunning. The inhibitors increase systemic arterial pressure impair myocyte contractility. In addition, radiation therapy to the mediastinum or left chest exacerbate cardiotoxicity these drugs also accelerated atherosclerosis, myocardial infarction, heart failure arrhythmias. Left ventricular ejection fraction measurements are most assess function in patients who receive chemo- radiation-therapy. However, echocardiographic determinations global longitudinal strain more sensitive for detection early systolic dysfunction. Information patient-risk stratification monitoring is presented guideli...
sci-hub.se 参考文章(88)
Manali Bhave, Steven T Rosen, Nausheen Akhter, Cardiovascular toxicity of biologic agents for cancer therapy. Oncology. ,vol. 28, pp. 482- 490 ,(2014)
Sinziana Seicean, Andreea Seicean, Juan Carlos Plana, G. Thomas Budd, Thomas H. Marwick, Effect of Statin Therapy on the Risk for Incident Heart Failure in Patients With Breast Cancer Receiving Anthracycline Chemotherapy Journal of the American College of Cardiology. ,vol. 60, pp. 2384- 2390 ,(2012) , 10.1016/J.JACC.2012.07.067
Sandra M. Swain, Fredrick S. Whaley, Michael S. Ewer, Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. ,vol. 97, pp. 2869- 2879 ,(2003) , 10.1002/CNCR.11407
Report on the international colloquium on cardio-oncology (rome, 12-14 march 2014). Ecancermedicalscience. ,vol. 8, pp. 433- 433 ,(2014) , 10.3332/ECANCER.2014.433
Baichun Yang, Thomas Papoian, Tyrosine kinase inhibitor (TKI)-induced cardiotoxicity: approaches to narrow the gaps between preclinical safety evaluation and clinical outcome Journal of Applied Toxicology. ,vol. 32, pp. 945- 951 ,(2012) , 10.1002/JAT.2813
Kamran Ghoreschi, Arian Laurence, John J O'Shea, Selectivity and therapeutic inhibition of kinases: to be or not to be? Nature Immunology. ,vol. 10, pp. 356- 360 ,(2009) , 10.1038/NI.1701
Teemu T. Junttila, Robert W. Akita, Kathryn Parsons, Carter Fields, Gail D. Lewis Phillips, Lori S. Friedman, Deepak Sampath, Mark X. Sliwkowski, Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941 Cancer Cell. ,vol. 15, pp. 429- 440 ,(2009) , 10.1016/J.CCR.2009.03.020
Fotiní Dodos, Teresa Halbsguth, Erland Erdmann, Uta C. Hoppe, Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults Clinical Research in Cardiology. ,vol. 97, pp. 318- 326 ,(2008) , 10.1007/S00392-007-0633-6
J Huelsenbeck, C Henninger, A Schad, K J Lackner, B Kaina, G Fritz, Inhibition of Rac1 signaling by lovastatin protects against anthracycline-induced cardiac toxicity Cell Death & Disease. ,vol. 2, pp. e190- e190 ,(2011) , 10.1038/CDDIS.2011.65
A.M. Gaya, R.F.U. Ashford, Cardiac complications of radiation therapy Clinical Oncology. ,vol. 17, pp. 153- 159 ,(2005) , 10.1016/J.CLON.2004.09.016